Also Known As
Victoza · Saxenda
Overview
Liraglutide is a GLP-1 analog with 97% homology to native GLP-1. FDA approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).
Mechanism of Action
Activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.
Quick Reference
Notes
Daily injection. Titrate up gradually.
Dosing Protocol
Pharmacokinetics
Administration
Special Instructions
Daily injection at same time. Can be used in pre-filled pen. Room temperature stable for 30 days after first use.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!